FDA won't re­or­ga­nize med­ical prod­uct cen­ters, Makary says in in­ter­view: 'I re­ject­ed that pro­pos­al'

The FDA plans to con­sol­i­date some ad­min­is­tra­tive func­tions, but won’t em­bark on a whole­sale re­or­ga­ni­za­tion of the re­view cen­ters that over­see drugs, bi­o­log­ics and med­ical …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER